1 of 11

IMAG/MSM Working Group on Multiscale Modeling and Viral Pandemics Mini Seminars

Feb 17, 2022

Welcome - The meeting will start at 3PM ET

 

NOTE: THE MEETING WILL BE RECORDED, STREAMED AND PUBLICLY AVAILABLE�FOR THOSE MEMBERS UNABLE TO ATTEND

Agenda

  1. Welcome
  2. Links, people, other info
  3. Social media links
  4. Quick Announcements
  5. Upcoming Mini-Seminars and Request for Future Speakers
  6. Juliano Ferrari Gianlupi, Indiana University, Coupled PK model of an antiviral and agent-based model reveal the importance of inter-cellular metabolism heterogeneity on treatment outcomes.
  7. Request for Further Business

 

2 of 11

People

Co-Lead: Reinhard Laubenbacher, PhD

Department of Medicine

Laboratory for Systems Medicine

University of Florida

reinhard.laubenbacher@medicine.ufl.edu

Co-Lead: James A. Glazier, PhD

Dept. of Intelligent Systems Engineering and Biocomplexity Institute

Indiana University, Bloomington

jaglazier@gmail.com

Web Administration, Slack: James P. Sluka, PhD

Dept. of Intelligent Systems Engineering and Biocomplexity Institute

Indiana University, Bloomington

jsluka@indiana.edu

Activities Coordination: Lorenzo Veschini, PhD

King’s College London

lorenzo.veschini@gmail.com

 

3 of 11

4 of 11

Please follow the�group on Twitter!

https://twitter.com/MsmViral

If you could re-tweet the weekly announcements �(there are usually two, one for each speaker) �that would help boost attendance and community awareness.

 

5 of 11

Announcements

Any short (~1 minute) items such as;

  • announcements
  • meetings
  • funding
  • publications
  • requests for help
  • ???

 

6 of 11

The Crick is currently recruiting specifically for early-career group leaders working in “Computational and theoretical biology”. Building a strong base in this area, which has been weakened by recent GL departures, is an important aspect of the Crick’s interdisciplinary research agenda.

The positions come with a very attractive core funded research package.

The call is now open with a deadline �for applications of March 10th.

www.crick.ac.uk/group-leader-recruitment

7 of 11

Schedule for Upcoming Meetings and mini-Seminars

Feb 24:

  1. Hayriye Gulbudak, University of Louisiana at Lafayette. Title: Coupled systems that have in-host and between-host components for various infectious diseases.
  2. TBD

Request for future speakers (Feb 17, 24, …)

8 of 11

Rules of the Meeting

Please mute your microphone and hold questions until after the presentations

9 of 11

Mini-SeminarCoupled PK model of an antiviral and agent-based model reveal the importance of inter-cellular metabolism heterogeneity on treatment outcomes

Juliano Ferrari GianlupiIndiana University

We extend our established agent-based multiscale computational model of infection of lung tissue by SARS-CoV-2 to include pharmacokinetic and pharmacodynamic models of remdesivir. We model remdesivir treatment for COVID-19; however, our methods are general to other viral infections and antiviral therapies. We investigate the effects of drug potency, drug dosing frequency, treatment initiation delay, antiviral half-life, and variability in cellular uptake and metabolism of remdesivir and its active metabolite, GS--443902, on treatment outcomes in a simulated patch of infected epithelial tissue. Non-spatial deterministic population models which treat all cells of a given class as identical can clarify how treatment dosage and timing influence infection dynamics, and treatment efficacy. However, they do not reveal how cell-to-cell variability affects treatment outcomes. Our simulations suggest that for a given treatment regime, depending on many factors including cell-to-cell variation in drug uptake and permeability increases the likelihood of uncontrolled infection in the tissue patch because the cells with the lowest internal levels of active metabolite act as super-spreaders within the tissue. The model predicts substantial variability in infection outcomes between similar tissue patches for different treatment options. In the models with cellular metabolism variability, antiviral doses have to be increased significantly (more than 50% depending on simulation parameters) to achieve the same treatment results as with the homogeneous cellular metabolism. After the presentations we will have breakout rooms for each of the speakers where you may discuss technical questions.

10 of 11

Requests for Input/Suggestions

  

 

We would like the subgroup leads to prepare brief presentations for the Thursday meetings, please let us know when you would like to present

Ideas/help for publicising our Thursday mini-seminars more effectively and for speakers to invite

Suggestions for agenda items and approaches to organizing the Steering Committee Meetings more effectively

There have also been a number of requests for more explicit statements of goals and tasks from the WG leadership, we would appreciate your suggestions

Please contact Reinhard Laubenbacher, James Glazier, James Sluka or Bruce Shapiro with your ideas on all of these issues

11 of 11

fini